MARKET WIREStocktwits • 19h ago
ARMP: Armata Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading IdeasStocktwits report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
Why ARMP Stock advanced +0.92% Today — RQD Quant Desk Flash
$3.28 +0.92% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.28
Armata Pharmaceuticals Inc. (ARMP) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $122.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ARMP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ARMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Armata Pharmaceuticals Inc. (NYSE: ARMP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.28 (+0.92% 1D, market cap $122.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARMP ranks #722 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ARMP compare to CHRS and HUMA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARMP carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CHRS (Coherus Oncology Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $128.3M) and HUMA (Humacyte Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $114.2M). Among the 5-stock peer group, ARMP leads on earnings multiple (N/A) while ARMP leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ARMP?
▼
Per ARMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921114), Armata Pharmaceuticals Inc. generated $102.6M in revenue (-13.7% YoY), -$173.8M in net income, and -$26.3M in free cash flow against $76.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.28 (-0.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARMP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY ARMP SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$3.63-15.4% Next Q
40
Q2 (-2Q)Grade E$3.07+12.4% Next Q
37
Q3 (-1Q)Grade E$3.45-4.9% Next Q
35
CurrentGrade E$3.28-9.2% Hist 90D α
32
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ARMP Turnaround Squeeze
While ARMP currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.15) and Max Pain ($3.44) forces dealer call-delta covering toward $15.73.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARMP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ARMP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ARMP Stock advanced +0.92% Today — RQD Quant Desk Flash
Armata Pharmaceuticals Inc. (ARMP) advanced +0.92% to $3.28, trading at 4% of its 52-week range ($2.75 – $14.98). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($2.75 – $14.98) with RSI-14 at 43.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.28 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ARMP Headlines & Catalysts
MARKET WIREYahoo Finance UK • 22h ago
Armata Pharmaceuticals, Inc. (ARMP) Seasonal returns chartYahoo Finance UK report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Armata Pharmaceuticals, Inc. Estimates – AMEX:ARMPTradingView report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREPR Newswire • 1d ago
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United StatesPR Newswire report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
iNtRON Biotechnology, Inc. (048530.KQ) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Innoviva, Inc. (INVA) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
COSCIENS Biopharma Inc. (CSCIF) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Hyloris Pharmaceuticals SA (HYL.BR) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 19h ago
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue EstimatesKrystal Biotech (KRYS) delivered earnings and revenue surprises of +11.41% and +2.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARMP)
- ✓Walkthrough of ARMP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ARMP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -66.70%📐 HORIZONTAL RANGE
2026-11-03O $3.25H $3.28L $3.25C $3.28VOL 46.7K
RES: $7.75SUP: $2.39SMA50: $4.15SMA200: $7.00
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ARMP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ARMP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ARMP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ARMP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARMP)
Health Care Rank #722 of 1016
⚔️ CHRS vs ARMP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ARMP vs. CHRS, HUMA, OTLK, CRDL)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Armata Pharmaceuticals Inc. (ARMP) ranks #722 by composite RQD confidence (32/100, grade E) and #631 by equity capitalization ($122.0M). Within this direct 5-issuer industry benchmark cohort, ARMP leads on earnings valuation at N/A trailing P/E, while ARMP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CRDL currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with ARMP at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARMP
ACTIVE
Armata Pharmaceuticals Inc. | E | 32/100 | — | — | -35.0% | +0.92% | $122.0M | Benchmark Subject |
| CHRS Coherus Oncology Inc. | E | 29/100 | — | — | -35.0% | -7.60% | $128.3M | /chrs-vs-armp → |
| HUMA Humacyte Inc. | E | 30/100 | — | -30.0% | -35.0% | -12.47% | $114.2M | /huma-vs-armp → |
| OTLK Outlook Therapeutics Inc. | D- | 35/100 | — | 4.0% | -35.0% | -5.15% | $114.0M | /otlk-vs-armp → |
| CRDL Cardiol Therapeutics Inc. (Class A) | D | 44/100 | — | — | — | -5.13% | $133.9M | /crdl-vs-armp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000921114In its most recent audited fiscal period (FY2025, filed 2025-12-31), Armata Pharmaceuticals Inc. (ARMP) reported GAAP revenue of $102.6M (-13.7% vs. FY2024 revenue of $118.8M , and -10.4% cumulative change since FY2023) , GAAP net income of -$173.8M, operating cash flow of -$25.8M, and free cash flow of -$26.3M (+33.3% YoY). On the balance sheet, ARMP closed FY2025 with $76.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $102.6M | -$173.8M | -$25.8M | -$26.3M | $76.9M | — |
| FY2024 (FY) | 2024-12-31 | $118.8M | -$18.9M | -$37.6M | -$39.4M | $86.4M | — |
| FY2023 (FY) | 2023-12-31 | $114.5M | -$69.0M | -$47.4M | -$47.4M | — | — |
3. ARMP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ARMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Armata Pharmaceuticals Inc. (NYSE: ARMP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.28 (+0.92% 1D, market cap $122.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARMP ranks #722 in composite RQD confidence.
How does ARMP compare to CHRS and HUMA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARMP carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CHRS (Coherus Oncology Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $128.3M) and HUMA (Humacyte Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $114.2M). Among the 5-stock peer group, ARMP leads on earnings multiple (N/A) while ARMP leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ARMP?
Per ARMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921114), Armata Pharmaceuticals Inc. generated $102.6M in revenue (-13.7% YoY), -$173.8M in net income, and -$26.3M in free cash flow against $76.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ARMP trading relative to its 50-day, 200-day, and 52-week technical levels?
ARMP last traded at $3.28 (+0.92% on volume of 46,747 shares), positioning the stock -20.96% below its 50-day simple moving average ($4.15) and -53.14% below its 200-day simple moving average ($7.00). Across its 52-week range of $2.75 to $14.98, ARMP sits at the 4.3% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.87 to $3.69).
ARMP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ARMP stock moving today?
Why ARMP Stock advanced +0.92% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 32/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ARMP — Armata Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:43:23Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ARMP scores 43 out of 100 and receives a D- grade, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 9/20 (ROIC -35%; FCF yield -21.77%), indicating the business is consuming rather than generating cash on a return basis. Whale 13F Flow scores 9/20 (institutional accumulation and options positioning), a weak signal. Insider Conviction scores 3/20 (SEC Form 4 and Congressional PTR cluster flow), the lowest pillar and a signal of limited insider confidence per the rating. Macro Regime Fit scores 12/20 (Beta 1.0; sector sensitivity), a moderate reading with market-level volatility exposure. Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), reflecting a middling but weak financial-health profile.
The lowest scores in insider conviction and institutional flow mean there is limited evidence of informed-capital support. Valuation tradeoffs are asymmetric: a low market capitalization ($120.8M) combined with a wide 52-week range ($2.75 - $14.98) reflects high volatility, and the current price of 3.28 sits near the lower end of that range.
Business
Armata Pharmaceuticals Inc. (ARMP) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the profile. Per the SEC financials, the company reported — revenue across FY 2023, FY 2024, and FY 2025, indicating no reported product revenue in the source data. Specific products, customers, and revenue model are —
Recent Catalysts & News Wire Analysis
Per the recent news feed, the headlines are predominantly market-wire and data-aggregator items referencing ARMP, all marked YELLOW. The most substantive catalyst is a PR Newswire item reporting that the company strengthened its intellectual property portfolio with two recent U.S. patent issuances. Other items (Stocktwits, Yahoo Finance UK, TradingView, and related seasonal-chart pages) are general market coverage without specific fundamental detail. Risk watch items include the absence of revenue and the cash decline noted in the financials. The Butterfly Supply-Chain Graph reports no supply chain and no proprietary signals.
Open Questions
- What is the company's cash runway given $8.7M in cash against FY 2025 FCF of $-26.3M, and what financing is planned?
- What explains the FY 2025 net loss of $-173.8M when operating loss was $-36.6M, and is there a non-operating or one-time component?
- What commercial or clinical milestones underpin the company's valuation absent reported revenue?
- What are the terms and remaining life of the recently issued U.S. patents referenced in the news feed?
- What is the company's debt position, given the source data reports debt as N/A while Debt/Equity is 0.5?
ARMP Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Armata Pharmaceuticals Inc. (ARMP) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stocktwits • 19h ago
ARMP: Armata Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 22h ago
Armata Pharmaceuticals, Inc. (ARMP) Seasonal returns chart Yahoo Finance UK report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Armata Pharmaceuticals, Inc. Estimates – AMEX:ARMP TradingView report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE PR Newswire • 1d ago
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States PR Newswire report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
iNtRON Biotechnology, Inc. (048530.KQ) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Innoviva, Inc. (INVA) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
COSCIENS Biopharma Inc. (CSCIF) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Hyloris Pharmaceuticals SA (HYL.BR) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ARMP Bull vs. Bear Conversation Board — What's Your Call at $3.28?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARMP 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $2.89 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ARMP (D- • RQD 43/100) a Buy at $3.28?
Welcome to the ARMP (Armata Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.62 (-20.1%)
Spot @ $3.28 Pump the brakes on ARMP — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ARMP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Armata Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $4.20 (+28.0%)
Spot @ $3.28 ARMP cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ARMP, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $3.28 (52-wk range $2.75 - $14.98), any beat on forward guidance forces shorts and underweight funds to chase.